YOLFTbeta
30

R&G PharmaStudies Co. Ltd. A

301333 · SHE · Healthcare / Biotechnology

53.06CNY-2.14 (-3.88%)

Price History

Full chart

Market Stats

Previous Close55.20
Open55.05
Day Range52.98 – 55.50
52-Week Range43.65 – 91.50
Volume1.66M
Market Cap6.44B
P/E (TTM)53.34
Forward P/E0.00
EPS1.25
Dividend Yield0.24%
Beta0.40
50-Day Avg57.44
200-Day Avg61.04

About

R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It offers drug clinical research and development integrated services. The company's services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology services. It serves pharmaceutical and medical device companies, and scientific research institutions. The company was founded in 2008 and is headquartered in Beijing, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Jie Wu M.B.A.
  • Employees2.65K
  • HeadquartersNorth Tower, Beijing, China, 100048, China
  • Websitehttps://www.rg-pharma.com

Leadership

  • Mr. Jie Wu M.B.A.Chairman & GM · b. 1961
  • Ms. Qian ZhaoChief Financial Officer · b. 1984
  • Ms. Leyan TengCOO, Senior VP & Director · b. 1972
  • Mr. Wei Wang EMBADeputy GM & Director · b. 1978
  • Mr. Jigang Li M.B.A.Senior VP & Chief Medical Officer · b. 1973
  • Dr. Shuqi LiSenior VP, Board Secretary & Director · b. 1965
  • Lilin ZhaoAccounting Supervisor

Financials

Income Statement

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue425.45M484.45M608.43M637.52M721.37M744.00M851.01M
Growth (%)-+13.87%+25.59%+4.78%+13.15%+3.14%+14.38%
Cost of Revenue240.37M294.29M375.25M402.62M434.34M468.08M555.36M
Gross Profit185.08M190.16M233.17M234.90M287.04M275.92M295.64M
Gross Margin43.50%39.25%38.32%36.85%39.79%37.09%34.74%
Operating Expense86.10M87.77M113.04M122.85M138.69M145.44M160.62M
Operating Income98.98M102.39M120.14M112.05M148.35M130.49M135.02M
Operating Margin23.27%21.14%19.75%17.58%20.56%17.54%15.87%
EBITDA115.92M124.18M150.81M164.41M217.65M197.54M193.62M
EBITDA Margin27.25%25.63%24.79%25.79%30.17%26.55%22.75%
Net Income82.63M83.84M99.24M113.45M162.53M140.22M136.90M
Net Income Margin19.42%17.31%16.31%17.79%22.53%18.85%16.09%
R&D31.32M34.70M41.19M49.99M52.86M56.83M61.97M
R&D as % of Total Revenue7.36%7.16%6.77%7.84%7.33%7.64%7.28%
Interest Expense--580.70K672.95K600.74K3.44M2.86M
Interest Expense % of Total Revenue--0.10%0.11%0.08%0.46%0.34%

Balance Sheet

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets446.86M536.36M677.47M1.88B2.07B2.34B2.40B
Total Liabilities197.12M199.38M239.66M289.35M319.17M500.09M423.89M
Total Equity237.74M322.83M422.53M1.59B1.75B1.83B1.97B
Cash274.10M293.82M361.60M1.52B991.48M1.07B1.13B

Cash Flow

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow103.48M44.10M114.57M130.47M192.56M154.76M114.20M
Capital Expenditure26.00M25.48M38.28M20.83M19.88M19.98M19.28M
Free Cash Flow77.47M18.62M76.29M109.64M172.68M134.78M94.93M
Dividends Paid----5.82M28.38M11.78M
FCF to OCF74.87%42.23%66.59%84.04%89.68%87.09%83.12%
Dividend Paid to FCF----3.37%21.06%12.41%

Earnings

Report DateSep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Apr 21, 2024Aug 29, 2024Oct 29, 2024Mar 28, 2025Apr 27, 2025Aug 28, 2025Oct 29, 2025Mar 28, 2026Apr 29, 2026Aug 28, 2026
EPS Estimate---------------
EPS Actual0.230.310.300.600.420.380.370.270.590.270.370.360.430.240.23
Surprise---------------
Timing-----Pre-market-Pre-market-Pre-market-----

Key Statistics & Ratios

Market Cap6.44B
Enterprise Value4.81B
Trailing P/E53.34
Forward P/E0.00
Price / Sales6.86
Price / Book3.22
EPS1.25
Book Value20.86
Revenue (TTM)939.31M
Gross Profit (TTM)295.11M
EBITDA114.61M
Profit Margin12.80%
Operating Margin10.04%
Return on Equity6.26%
Return on Assets3.06%
Shares Outstanding96.58M
Shares Float38.00M
Beta0.40
Dividend Yield0.24%
Dividend Rate0.16
Payout Ratio12.78%

Dividends

20261×
0.16Jul 3, 2026
20251×
0.16Jul 8, 2025
20241×
0.20Jul 5, 2024
20231×
0.25Jun 29, 2023

Stock Splits

  • Jun 29, 20231.6:1